Ibio Inc (IBIO) 0.57 $IBIO Implications of Cour
Post# of 273249
Posted On: 09/27/2016 5:34:57 AM
Ibio Inc (IBIO) 0.57 $IBIO
Implications of Court Decision in Favor of iBio Against Fraunhofer
Marketwire Canada - Mon Aug 15, 7:30AM CDT
NEW YORK, NY--(Marketwired - Aug 15, 2016) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, commented further today on the impact of the recent Court decision in favor of iBio in its action against Fraunhofer and particularly to prevent Fraunhofer's August 8th press release from misleading the public about the implications of the decision.
IBIO: 0.57 (+0.01)
iBio, Inc.'s Claims Against Fraunhofer Affirmed by Delaware Chancery Court
Marketwire Canada - Thu Aug 04, 7:31AM CDT
NEW YORK, NY--(Marketwired - Aug 4, 2016) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced today that the Delaware Court of Chancery, where litigation brought by iBio against Fraunhofer USA Inc. has been pending, issued a decisive determination on July 29, 2016, in favor of iBio and against Fraunhofer. The Court affirmed iBio's exclusive ownership of all proprietary rights of any kind to technology in the area of plant-based technologies, techniques and methodologies, developed or acquired by Fraunhofer prior to or during the principal contractual period of iBio's engagement of Fraunhofer, which began in 2004 and continued until the end of calendar 2014. The Court specifically found that iBio is the exclusive owner of all such property and is entitled to have a technology transfer and assignment of all such property without the conditions Fraunhofer sought to impose.
IBIO: 0.57 (+0.01)
Texas A&M University System and iBio Execute Joint Development Agreement for Plant-Produced Pharmaceuticals
Marketwire Canada - Tue Jun 07, 7:31AM CDT
NEW YORK, NY--(Marketwired - Jun 7, 2016) - iBio, Inc. (NYSE MKT: IBIO) - The Texas A & M University System (including Texas A & M University AgriLife Research, and the Texas A & M Institute of Infectious Animal Diseases (IIAD)) ("TAMUS"
, has executed a joint development agreement with iBio, Inc., and its subsidiary, iBio CMO LLC in Bryan/College Station, Texas ("iBio" for the establishment of a collaborative program in plant-produced pharmaceuticals.
IBIO: 0.57 (+0.01)
World Malaria Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wh66xl/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malaria Overview - Therapeutics Development - Pipeline Products for Malaria - Overview - Pipeline Products for Malaria - Comparative Analysis - Malaria - Therapeutics under Development by Companies - Malaria - Therapeutics under Investigation by Universities/Institutes - Malaria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malaria - Products under Development by Companies - Malaria - Products under Investigation by Universities/Institutes - Malaria - Companies Involved in Therapeutics Development - Partial List - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actelion Ltd - Agilvax, Inc. - Akshaya Bio Inc. - Amura Holdings Limited - Artificial Cell Technologies, Inc. - AstraZeneca Plc - Bharat Biotech International Limited - Callaghan Innovation Research Ltd. - Carna Biosciences, Inc. - CEL-SCI Corporation - Celgene Corporation - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Cilian AG - Clevexel Pharma SAS - Daiichi Sankyo Company, Limited - DesignMedix, Inc. - Eisai Co., Ltd. - Folia Biotech Inc. - Genocea Biosciences, Inc. - GenVec, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - iBio, Inc. - Imaxio SA - Immtech Pharmaceuticals, Inc. - Immunitor, Inc. - Inovio Pharmaceuticals, Inc. - IPCA Laboratories Limited - iQur Limited - IRBM Science Park SpA - Jenrin Discovery, Inc. - Jomaa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/wh66xl/malaria
CVM: 0.44 (+0.02), GNCA: 5.54 (+0.05), GSK: 42.96 (-0.46), INO: 9.44 (-0.06), AZN: 33.55 (-0.42), IBIO: 0.57 (+0.01), CELGZ: 1.21 (-0.03)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 7.40 (+0.05), EBS: 28.10 (-0.26), BOTA: 1.55 (-0.04), VBIV: 3.76 (-0.14), GSK: 42.96 (-0.46), GILD: 80.62 (-0.75), MRK: 62.15 (-0.81), IBIO: 0.57 (+0.01)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 21.95 (-0.80), BCRX: 4.71 (unch), ARWR: 7.04 (-0.18), SHPG: 199.09 (-3.96), IBIO: 0.57 (+0.01), DYAX: 38.04 (-0.37)
iBio Forms Joint Venture CMO for Large-Scale Pharmaceuticals Manufacturing in Green Plants and Accepts Additional Investment
Marketwired - Thu Jan 14, 8:02AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the formation of a joint venture with affiliates of Eastern Capital Limited (the "Eastern Affiliates" to develop and manufacture plant-made pharmaceuticals.
IBIO: 0.57 (+0.01)
Yellow Fever Pipeline Review, H2 2015 - Analysis, Technologies & Forecasts
M2 - Thu Jan 07, 11:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/w3nqnl/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Yellow Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Yellow Fever - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adamas Pharmaceuticals, Inc. - BioCryst Pharmaceuticals, Inc. - iBio, Inc. - Johnson & Johnson - Myelo Therapeutics GmbH - NewLink Genetics Corporation - Panacea Biotec Limited - Themis Bioscience GmbH For more information visit http://www.researchandmarkets.com/research/w3...llow_fever
JNJ: 117.78 (-1.03), BCRX: 4.71 (unch), NLNK: 12.55 (-0.32), IBIO: 0.57 (+0.01)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.62 (-0.01), GALT: 2.52 (-0.21), LLY: 79.52 (-1.64), BMY: 55.48 (-1.00), GLPG: 66.68 (-4.32), GILD: 80.62 (-0.75), IBIO: 0.57 (+0.01), TEVA: 50.27 (-1.20), FGEN: 21.78 (-0.38), CELGZ: 1.21 (-0.03)
Global Idiopathic Pulmonary Fibrosis Therapeutics Pipeline Review 2015
M2 - Wed Jan 06, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/63sldq/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Idiopathic Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview - Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis - Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies - Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Pipeline Products Glance - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Idiopathic Pulmonary Fibrosis - Products under Development by Companies - Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - GenKyoTex S.A. - Gilead Sciences, Inc. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - MedImmune, LLC - Moerae Matrix, Inc. - MorphoSys AG - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. - Respira Therapeutics, Inc. - Rhizen Pharmaceuticals SA - Ribomic Inc. - Sanofi - Teva Pharmaceutical Industries Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/63sldq/idiopathic
BMY: 55.48 (-1.00), GLPG: 66.68 (-4.32), GILD: 80.62 (-0.75), CGEN: 6.60 (-0.21), IBIO: 0.57 (+0.01), TEVA: 50.27 (-1.20), FGEN: 21.78 (-0.38), CELGZ: 1.21 (-0.03)
Fabry Disease Therapeutics Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8r98p/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Alexion Pharmaceuticals, Inc. - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Genz-682452 - GZ-402671 - lucerastat - migalastat hydrochloride - migalastat hydrochloride Enzyme Replacement Therapy Biobetter - MOSS-AGAL - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease - Recombinant Enzymes for Pompe, Fabry and Hunter Diseases For more information visit http://www.researchandmarkets.com/research/h8...ry_disease
ALXN: 124.51 (-2.71), IBIO: 0.57 (+0.01), FOLD: 7.52 (-0.11)
iBio Continues Global Expansion of Intellectual Property
Marketwired - Mon Nov 30, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, announced it has received notice from the European Patent Office that the opposition period for a patent granted to iBio has expired and no opposition has been filed.
IBIO: 0.57 (+0.01)
Scientific Insights Into IBIO-CFB03 Presented at American College of Rheumatology Annual Meeting
Marketwired - Thu Nov 19, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, announced the presentation at the annual meeting on November 10 of the American College of Rheumatology (ACR) in San Francisco, CA of new information on the mechanism of action of iBio's proprietary product candidate for the treatment of fibrotic diseases, IBIO-CFB03.
IBIO: 0.57 (+0.01)
Global Human Papillomavirus (HPV) Associated Cancer Pipeline Review, H2 2015 - 32 Companies & 54 Drug Profiles
M2 - Mon Nov 09, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/jsltn6/human) has announced the addition of the "Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Admedus Ltd - Advaxis, Inc. - Antigen Express, Inc. - Bionor Pharma ASA - Cancer Research Technology Limited - Cancer Therapeutics CRC Pty Ltd - Chong Kun Dang Pharmaceutical Corp. - Etubics Corporation - EyeGene, Inc. - Formune S.L. - Genexine, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onconova Therapeutics, Inc. - Oryx GmbH & Co. KG - Prima BioMed Ltd. - Profectus BioSciences, Inc. - Redbiotec AG - Shantha Biotechnics Limited - Sirnaomics, Inc. - Theravectys SA - Transgene SA - Vaccibody AS - Virometix AG - ViroStatics, srl For more information visit http://www.researchandmarkets.com/research/jsltn6/human
ADXS: 10.54 (-0.26), ONTX: 3.06 (-0.04), INO: 9.44 (-0.06), KITE: 54.98 (+0.41), MRK: 62.15 (-0.81), IBIO: 0.57 (+0.01), NVS: 80.73 (-0.75), KPTI: 9.35 (unch)
Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 11.06 (-0.35), TTPH: 3.85 (+0.02), ADRO: 13.24 (-1.30), EBS: 28.10 (-0.26), UTHR: 125.57 (-1.64), BMY: 55.48 (-1.00), PFNX: 8.78 (-0.32), PIP: 2.88 (-0.01), IBIO: 0.57 (+0.01), OGEN: 0.53 (unch)
Systemic Sclerosis (Scleroderma) Pipeline Review, H2 2015 - 24 Companies & 35 Drug Profiles
M2 - Fri Nov 06, 8:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8xzj6/systemic) has announced the addition of the "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Angion Biomedica Corp. - arGentis Pharmaceuticals, LLC - Bayer AG - BioLineRx, Ltd. - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Celgene Corporation - Corbus pharmaceuticals, Inc. - CSL Limited - Daval International Limited - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - Fibrocell Science, Inc. - GlaxoSmithKline Plc - iBio, Inc. - Inventiva SAS - Kadmon Corporation, LLC - MedImmune, LLC - NovaLead Pharma Pvt. Ltd. - Peptinov SAS - Stratatech Corporation - Vida Therapeutics Inc. - VivaCell Biotechnology Espana S.L. Drug Profiles - abatacept - acALY-18 - Aimspro - ANG-3070 - ARG-201 - belimumab - BL-1110 - BOT-191 - C-82 - CC-220 - disitertide - factor XIII (human) - FCX-013 - GSK-2330811 - IBIOCFB-03 - inebilizumab - IVA-337 - JBT-101 - KD-025 - NLP-491 - Oligonucleotide for Scleroderma - onabotulinumtoxin A - P-17 - PAT-048 - PDX-002 - PPV-06 - riociguat - Small Molecule to Inhibit NFkB for Immunology and Oncology - Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis - StrataGraft Skin Tissue - Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - tocilizumab - VCE-0048 - VEDA-1209 - VTI-1000 Series For more information visit http://www.researchandmarkets.com/research/v8xzj6/systemic
AGN: 238.68 (-5.26), FCSC: 0.74 (-0.05), IBIO: 0.57 (+0.01), GSK: 42.96 (-0.46), BMY: 55.48 (-1.00), CELGZ: 1.21 (-0.03)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 309.82 (-2.76), UTHR: 125.57 (-1.64), CTIC: 0.38 (unch), CHRS: 29.69 (-0.31), JNJ: 117.78 (-1.03), IBIO: 0.57 (+0.01), EBS: 28.10 (-0.26), AMGN: 173.53 (-1.27), SPPI: 4.66 (-0.06), LLY: 79.52 (-1.64), GSK: 42.96 (-0.46), ANIK: 45.82 (-1.10), NVO: 44.43 (-0.45), BAX: 47.20 (-0.29), MRK: 62.15 (-0.81), NVS: 80.73 (-0.75)
Implications of Court Decision in Favor of iBio Against Fraunhofer
Marketwire Canada - Mon Aug 15, 7:30AM CDT
NEW YORK, NY--(Marketwired - Aug 15, 2016) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, commented further today on the impact of the recent Court decision in favor of iBio in its action against Fraunhofer and particularly to prevent Fraunhofer's August 8th press release from misleading the public about the implications of the decision.
IBIO: 0.57 (+0.01)
iBio, Inc.'s Claims Against Fraunhofer Affirmed by Delaware Chancery Court
Marketwire Canada - Thu Aug 04, 7:31AM CDT
NEW YORK, NY--(Marketwired - Aug 4, 2016) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced today that the Delaware Court of Chancery, where litigation brought by iBio against Fraunhofer USA Inc. has been pending, issued a decisive determination on July 29, 2016, in favor of iBio and against Fraunhofer. The Court affirmed iBio's exclusive ownership of all proprietary rights of any kind to technology in the area of plant-based technologies, techniques and methodologies, developed or acquired by Fraunhofer prior to or during the principal contractual period of iBio's engagement of Fraunhofer, which began in 2004 and continued until the end of calendar 2014. The Court specifically found that iBio is the exclusive owner of all such property and is entitled to have a technology transfer and assignment of all such property without the conditions Fraunhofer sought to impose.
IBIO: 0.57 (+0.01)
Texas A&M University System and iBio Execute Joint Development Agreement for Plant-Produced Pharmaceuticals
Marketwire Canada - Tue Jun 07, 7:31AM CDT
NEW YORK, NY--(Marketwired - Jun 7, 2016) - iBio, Inc. (NYSE MKT: IBIO) - The Texas A & M University System (including Texas A & M University AgriLife Research, and the Texas A & M Institute of Infectious Animal Diseases (IIAD)) ("TAMUS"
, has executed a joint development agreement with iBio, Inc., and its subsidiary, iBio CMO LLC in Bryan/College Station, Texas ("iBio" for the establishment of a collaborative program in plant-produced pharmaceuticals. IBIO: 0.57 (+0.01)
World Malaria Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wh66xl/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malaria Overview - Therapeutics Development - Pipeline Products for Malaria - Overview - Pipeline Products for Malaria - Comparative Analysis - Malaria - Therapeutics under Development by Companies - Malaria - Therapeutics under Investigation by Universities/Institutes - Malaria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malaria - Products under Development by Companies - Malaria - Products under Investigation by Universities/Institutes - Malaria - Companies Involved in Therapeutics Development - Partial List - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actelion Ltd - Agilvax, Inc. - Akshaya Bio Inc. - Amura Holdings Limited - Artificial Cell Technologies, Inc. - AstraZeneca Plc - Bharat Biotech International Limited - Callaghan Innovation Research Ltd. - Carna Biosciences, Inc. - CEL-SCI Corporation - Celgene Corporation - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Cilian AG - Clevexel Pharma SAS - Daiichi Sankyo Company, Limited - DesignMedix, Inc. - Eisai Co., Ltd. - Folia Biotech Inc. - Genocea Biosciences, Inc. - GenVec, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - iBio, Inc. - Imaxio SA - Immtech Pharmaceuticals, Inc. - Immunitor, Inc. - Inovio Pharmaceuticals, Inc. - IPCA Laboratories Limited - iQur Limited - IRBM Science Park SpA - Jenrin Discovery, Inc. - Jomaa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/wh66xl/malaria
CVM: 0.44 (+0.02), GNCA: 5.54 (+0.05), GSK: 42.96 (-0.46), INO: 9.44 (-0.06), AZN: 33.55 (-0.42), IBIO: 0.57 (+0.01), CELGZ: 1.21 (-0.03)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 7.40 (+0.05), EBS: 28.10 (-0.26), BOTA: 1.55 (-0.04), VBIV: 3.76 (-0.14), GSK: 42.96 (-0.46), GILD: 80.62 (-0.75), MRK: 62.15 (-0.81), IBIO: 0.57 (+0.01)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 21.95 (-0.80), BCRX: 4.71 (unch), ARWR: 7.04 (-0.18), SHPG: 199.09 (-3.96), IBIO: 0.57 (+0.01), DYAX: 38.04 (-0.37)
iBio Forms Joint Venture CMO for Large-Scale Pharmaceuticals Manufacturing in Green Plants and Accepts Additional Investment
Marketwired - Thu Jan 14, 8:02AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the formation of a joint venture with affiliates of Eastern Capital Limited (the "Eastern Affiliates"
to develop and manufacture plant-made pharmaceuticals. IBIO: 0.57 (+0.01)
Yellow Fever Pipeline Review, H2 2015 - Analysis, Technologies & Forecasts
M2 - Thu Jan 07, 11:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/w3nqnl/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Yellow Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Yellow Fever - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adamas Pharmaceuticals, Inc. - BioCryst Pharmaceuticals, Inc. - iBio, Inc. - Johnson & Johnson - Myelo Therapeutics GmbH - NewLink Genetics Corporation - Panacea Biotec Limited - Themis Bioscience GmbH For more information visit http://www.researchandmarkets.com/research/w3...llow_fever
JNJ: 117.78 (-1.03), BCRX: 4.71 (unch), NLNK: 12.55 (-0.32), IBIO: 0.57 (+0.01)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.62 (-0.01), GALT: 2.52 (-0.21), LLY: 79.52 (-1.64), BMY: 55.48 (-1.00), GLPG: 66.68 (-4.32), GILD: 80.62 (-0.75), IBIO: 0.57 (+0.01), TEVA: 50.27 (-1.20), FGEN: 21.78 (-0.38), CELGZ: 1.21 (-0.03)
Global Idiopathic Pulmonary Fibrosis Therapeutics Pipeline Review 2015
M2 - Wed Jan 06, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/63sldq/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Idiopathic Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview - Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis - Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies - Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Pipeline Products Glance - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Idiopathic Pulmonary Fibrosis - Products under Development by Companies - Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - GenKyoTex S.A. - Gilead Sciences, Inc. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - MedImmune, LLC - Moerae Matrix, Inc. - MorphoSys AG - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. - Respira Therapeutics, Inc. - Rhizen Pharmaceuticals SA - Ribomic Inc. - Sanofi - Teva Pharmaceutical Industries Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/63sldq/idiopathic
BMY: 55.48 (-1.00), GLPG: 66.68 (-4.32), GILD: 80.62 (-0.75), CGEN: 6.60 (-0.21), IBIO: 0.57 (+0.01), TEVA: 50.27 (-1.20), FGEN: 21.78 (-0.38), CELGZ: 1.21 (-0.03)
Fabry Disease Therapeutics Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8r98p/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Alexion Pharmaceuticals, Inc. - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Genz-682452 - GZ-402671 - lucerastat - migalastat hydrochloride - migalastat hydrochloride Enzyme Replacement Therapy Biobetter - MOSS-AGAL - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease - Recombinant Enzymes for Pompe, Fabry and Hunter Diseases For more information visit http://www.researchandmarkets.com/research/h8...ry_disease
ALXN: 124.51 (-2.71), IBIO: 0.57 (+0.01), FOLD: 7.52 (-0.11)
iBio Continues Global Expansion of Intellectual Property
Marketwired - Mon Nov 30, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, announced it has received notice from the European Patent Office that the opposition period for a patent granted to iBio has expired and no opposition has been filed.
IBIO: 0.57 (+0.01)
Scientific Insights Into IBIO-CFB03 Presented at American College of Rheumatology Annual Meeting
Marketwired - Thu Nov 19, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, announced the presentation at the annual meeting on November 10 of the American College of Rheumatology (ACR) in San Francisco, CA of new information on the mechanism of action of iBio's proprietary product candidate for the treatment of fibrotic diseases, IBIO-CFB03.
IBIO: 0.57 (+0.01)
Global Human Papillomavirus (HPV) Associated Cancer Pipeline Review, H2 2015 - 32 Companies & 54 Drug Profiles
M2 - Mon Nov 09, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/jsltn6/human) has announced the addition of the "Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Admedus Ltd - Advaxis, Inc. - Antigen Express, Inc. - Bionor Pharma ASA - Cancer Research Technology Limited - Cancer Therapeutics CRC Pty Ltd - Chong Kun Dang Pharmaceutical Corp. - Etubics Corporation - EyeGene, Inc. - Formune S.L. - Genexine, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onconova Therapeutics, Inc. - Oryx GmbH & Co. KG - Prima BioMed Ltd. - Profectus BioSciences, Inc. - Redbiotec AG - Shantha Biotechnics Limited - Sirnaomics, Inc. - Theravectys SA - Transgene SA - Vaccibody AS - Virometix AG - ViroStatics, srl For more information visit http://www.researchandmarkets.com/research/jsltn6/human
ADXS: 10.54 (-0.26), ONTX: 3.06 (-0.04), INO: 9.44 (-0.06), KITE: 54.98 (+0.41), MRK: 62.15 (-0.81), IBIO: 0.57 (+0.01), NVS: 80.73 (-0.75), KPTI: 9.35 (unch)
Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 11.06 (-0.35), TTPH: 3.85 (+0.02), ADRO: 13.24 (-1.30), EBS: 28.10 (-0.26), UTHR: 125.57 (-1.64), BMY: 55.48 (-1.00), PFNX: 8.78 (-0.32), PIP: 2.88 (-0.01), IBIO: 0.57 (+0.01), OGEN: 0.53 (unch)
Systemic Sclerosis (Scleroderma) Pipeline Review, H2 2015 - 24 Companies & 35 Drug Profiles
M2 - Fri Nov 06, 8:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8xzj6/systemic) has announced the addition of the "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Angion Biomedica Corp. - arGentis Pharmaceuticals, LLC - Bayer AG - BioLineRx, Ltd. - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Celgene Corporation - Corbus pharmaceuticals, Inc. - CSL Limited - Daval International Limited - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - Fibrocell Science, Inc. - GlaxoSmithKline Plc - iBio, Inc. - Inventiva SAS - Kadmon Corporation, LLC - MedImmune, LLC - NovaLead Pharma Pvt. Ltd. - Peptinov SAS - Stratatech Corporation - Vida Therapeutics Inc. - VivaCell Biotechnology Espana S.L. Drug Profiles - abatacept - acALY-18 - Aimspro - ANG-3070 - ARG-201 - belimumab - BL-1110 - BOT-191 - C-82 - CC-220 - disitertide - factor XIII (human) - FCX-013 - GSK-2330811 - IBIOCFB-03 - inebilizumab - IVA-337 - JBT-101 - KD-025 - NLP-491 - Oligonucleotide for Scleroderma - onabotulinumtoxin A - P-17 - PAT-048 - PDX-002 - PPV-06 - riociguat - Small Molecule to Inhibit NFkB for Immunology and Oncology - Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis - StrataGraft Skin Tissue - Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - tocilizumab - VCE-0048 - VEDA-1209 - VTI-1000 Series For more information visit http://www.researchandmarkets.com/research/v8xzj6/systemic
AGN: 238.68 (-5.26), FCSC: 0.74 (-0.05), IBIO: 0.57 (+0.01), GSK: 42.96 (-0.46), BMY: 55.48 (-1.00), CELGZ: 1.21 (-0.03)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 309.82 (-2.76), UTHR: 125.57 (-1.64), CTIC: 0.38 (unch), CHRS: 29.69 (-0.31), JNJ: 117.78 (-1.03), IBIO: 0.57 (+0.01), EBS: 28.10 (-0.26), AMGN: 173.53 (-1.27), SPPI: 4.66 (-0.06), LLY: 79.52 (-1.64), GSK: 42.96 (-0.46), ANIK: 45.82 (-1.10), NVO: 44.43 (-0.45), BAX: 47.20 (-0.29), MRK: 62.15 (-0.81), NVS: 80.73 (-0.75)
(0)
(0)Scroll down for more posts ▼